GlassScriptPhysician profile
Matthew S Lief
NPI 1902872096
$9,046.48
in general payments reported to CMS, 2019-2025
32 companies · $997 in 2025
The $997 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $1,176 · 2021: $1,604 · 2022: $1,515 · 2023: $1,525 · 2024: $896 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696 · Travel and Lodging: $407 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.04 |
| Travel and Lodging | $407.16 |
| Education | $314.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,893.34 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Antares Pharma, INC. | $1,408.41 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Boston Scientific Corporation | $1,074.52 | 2020-2023 | Rezum Generator |
| Valencia Technologies Corporation | $589.76 | 2023-2024 | Ecoin Device Kit |
| Zyla Life Sciences, INC. | $562.26 | 2019-2020 | |
| Pfizer INC. | $469.50 | 2019-2025 | |
| Astellas Pharma US INC | $416.16 | 2019-2025 | Xtandi |
| Tolmar, INC. | $225.27 | 2023-2025 | Eligard, Jatenzo |
| Ferring Pharmaceuticals INC. | $174.62 | 2019-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $146.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.29 | 2025 | |
| Olympus America INC. | $111.47 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $102.69 | 2021-2022 | |
| Coloplast Corp | $99.03 | 2020-2025 | |
| Verity Pharmaceuticals INC. | $92.82 | 2024-2025 | Tlando |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $64.75 | 2021 | |
| Halozyme INC | $61.46 | 2023 | |
| Sumitomo Pharma America, INC. | $54.41 | 2024-2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $49.05 | 2022-2023 | |
| Axonics, INC. | $42.63 | 2023 | Axonics |
| Rochester Medical Corporation | $36.03 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| C. R. Bard, INC. & Subsidiaries | $26.58 | 2020 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Lynparza |
| Accord Healthcare, INC. | $25.28 | 2024 | |
| Progenics Pharmaceuticals, INC. | $23.79 | 2022 | |
| Myriad Genetic Laboratories, INC. | $22.67 | 2023 | Prolaris |
| Convatec INC. | $19.26 | 2022 | |
| Agiliti Surgical, INC. | $18.51 | 2019 | |
| Metuchen Pharmaceuticals | $16.68 | 2020 | |
| Telix Pharmaceuticals | $15.81 | 2023 | Illuccix |
| Amgen INC. | $14.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lief listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.